Towards individualised medicine for airways disease: Identifying clinical phenotype groups

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 1033-1034

  Travers, J ^a   Weatherall, M ^a,b   Fingleton, J ^a,c   Beasley, R ^a,d  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d WELLINGTON HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CIGARETTE SMOKE; IMMUNOGLOBULIN E; NITRIC OXIDE;

ALLERGIC ASTHMA; BRONCHODILATOR REVERSIBILITY TEST; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION AND REGRESSION TREE; CLUSTER ANALYSIS; DISEASE CLASSIFICATION; EMPHYSEMA; EOSINOPHILIA; EVIDENCE BASED MEDICINE; EXHALED NITRIC OXIDE FRACTION; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; PERSONALIZED MEDICINE; PHENOTYPE; POSTBRONCHODILATOR CHANGE IN FORCED EXPIRATORY VOLUME IN ONE SECOND; POSTBRONCHODILATOR FORCED EXPIRATORY VOLUME IN ONE SECOND; PREBRONCHODILATOR FORCED EXPIRATORY VOLUME IN ONE SECOND; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT PARAMETERS; SMOKING; SPUTUM ANALYSIS; STATISTICAL ANALYSIS;

ASTHMA; CLUSTER ANALYSIS; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84860342162     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00122811     Document Type: Letter

References (10)

1. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
2. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121: Suppl. 5, 121S-126S. (Pubitemid 34497328)
3. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62: 1043-1049. (Pubitemid 350206195)
4. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-1485.
5. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073. (Pubitemid 36583301)
6. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34: 812-818.
7. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
8. Fingleton J, Weatherall M, Beasley R. Towards individualised treatment in COPD. Thorax 2011; 66: 363-364.
9. Crawley MJ. The R Book. Chichester, John Wiley and Sons, 2007.
10. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-323.